EUVIMEDEUVIMED entdecken
Crossref

Myeloperoxidase/ASGPR Dual‐Targeting Self‐Amplifying Nanoplatform for Synergistic Anti‐Metastatic Therapy of Hepatocellular Carcinoma

Le Wang, Xiang Wang, Hengrui Li, Yihan Ma, Peter H Seeberger iD, Jing Hu iD, Jian Yin iD

Small · 2026

DOI: 10.1002/smll.74938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2026. Verfasst von Le Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Repub…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Peroxidase, Nanoparticles. Die Arbeit nennt 68 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) remains highly lethal due to a complex tumor microenvironment (TME) that limits therapeutic efficacy. Herein, a dual‐targeted nanotherapeutic platform (SC@GRT‐COF‐366) based on a covalent organic framework (COF‐366) is reported for synergistic HCC treatment. This multifunctional system integrates chemotherapy, photodynamic therapy, autophagy regulation, and TME remodeling to synergistically inhibit tumor metastasis. Gal‐D5HT‐modified nanoparticles achieve enhanced HCC targeting via myeloperoxidase (MPO)‐responsive aggregation in the inflammatory microenvironment and ASGPR‐mediated uptake. Upon light irradiation, COF‐366 generates singlet oxygen to induce tumor cell apoptosis and simultaneously enhances MPO expression and neutrophil infiltration, further amplifying MPO‐triggered nanoparticle aggregation and establishing a self‐amplifying retention‐therapy cascade. Meanwhile, co‐loaded sorafenib and chloroquine enable combined chemotherapy and autophagy inhibition, effectively overcoming drug resistance. In vivo results demonstrate significantly enhanced and prolonged tumor accumulation compared with single‐targeted systems, resulting in a tumor growth inhibition rate of 93.5 ± 1.02% in subcutaneous models and effective suppression of lung metastasis in orthotopic HCC models. Notably, treatment markedly reduces neutrophil extracellular traps (NETs) formation, indicating favorable remodeling of the tumor immune microenvironment. Collectively, this multifunctional COF‐based nanoplatform integrates dual‐targeted delivery, amplified tumor retention, and synergistic multimodal therapy, offering a promising strategy for advanced HCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularPeroxidaseNanoparticlesHumansAnimalsCell Line, TumorNeoplasm MetastasisTumor MicroenvironmentSorafenibChloroquineAutophagyMice, Inbred BALB CPhotochemotherapyMiceMice, Nude

Stichwörter der Autor:innen

anti‐metastatic therapyasialoglycoprotein receptordual targetinghepatocellular carcinomamyeloperoxidasetumor microenvironment

Substanzen

PeroxidaseSorafenibChloroquine

Autor:innen und Institutionen

  • Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Republic of China.
  • Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.
  • Wuxi School of Medicine, Jiangnan University, Wuxi, People's Republic of China.
  • Innovation Center for vaccine engineering, Jiangnan University, Wuxi, People's Republic of China.
  • Institute of Future Food Technology, JITRI, Yixing, People's Republic of China.

ORCID-Profile: Peter H Seeberger, Jing Hu, Jian Yin

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Pilot Research Program of WIIRI
  • Max Planck Society International Partner Group Program, and China Scholarship Council
  • the Open Project of key Laboratory of Carbohydrate Chemistry and Biotechnology, Jiangnan university, Ministry of Education
  • National Key Research and Development Program of China

Zitieren

APA

Wang, L., Wang, X., Li, H., Ma, Y., Seeberger, P. H., Hu, J., & Yin, J. (2026). Myeloperoxidase/ASGPR Dual‐Targeting Self‐Amplifying Nanoplatform for Synergistic Anti‐Metastatic Therapy of Hepatocellular Carcinoma. Small. https://doi.org/10.1002/smll.74938

Vancouver

Wang L, Wang X, Li H, Ma Y, Seeberger PH, Hu J, et al. Myeloperoxidase/ASGPR Dual‐Targeting Self‐Amplifying Nanoplatform for Synergistic Anti‐Metastatic Therapy of Hepatocellular Carcinoma. Small. 2026. doi:10.1002/smll.74938

BibTeX
@article{Wang2026,
  author = {Wang, Le and Wang, Xiang and Li, Hengrui and Ma, Yihan and Seeberger, Peter H and Hu, Jing and Yin, Jian},
  title = {Myeloperoxidase/ASGPR Dual‐Targeting Self‐Amplifying Nanoplatform for Synergistic Anti‐Metastatic Therapy of Hepatocellular Carcinoma},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.74938}
}
Kostenlos starten →